<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04914026</url>
  </required_header>
  <id_info>
    <org_study_id>2015/1475</org_study_id>
    <nct_id>NCT04914026</nct_id>
  </id_info>
  <brief_title>MicroRNA as Markers in Testicular Cancer</brief_title>
  <official_title>MicroRNA-371 as Markers for Disease Activity and as a Tool to Monitor the Effect of Chemotherapy and Early Detection of Recurrence in Patients With Testicular Germ Cell Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Fonna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is establish the performance of miR371 in management of&#xD;
      testicular cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of the study is to asses the sensitivity and specificity of&#xD;
      microRNA-371a-5p (miR371) in detection of viable testicular germ tumour cells. To assess the&#xD;
      utility of miR371 at orchiectomy, during treatment and surveillance and in early detection of&#xD;
      recurrence.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 31, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>miR371 as a biomarker in testicular germ cell cancer at orchiectomy</measure>
    <time_frame>5 years</time_frame>
    <description>To estimate the sensitivity and specificity of miR371 in identifying viable tumour cells at diagnosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>miR371 as a biomarker in testicular germ cell cancer at RPLND</measure>
    <time_frame>5 years</time_frame>
    <description>To estimate the sensitivity and specificity of miR371 in identifying viable tumour cells at RPLND</description>
  </primary_outcome>
  <primary_outcome>
    <measure>miR371 as a biomarker in testicular germ cell cancer during chemotherapy treatment</measure>
    <time_frame>5 years</time_frame>
    <description>To estimate the performance of miR371 in monitoring of treatment efficiency (chemotherapy)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>miR371 as a biomarker in testicular germ cell cancer and detection of recurrence</measure>
    <time_frame>5 years</time_frame>
    <description>To estimate the performance of miR371 in (early) detection of recurrence</description>
  </primary_outcome>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Testicular Germ Cell Cancer</condition>
  <condition>Seminoma</condition>
  <condition>Non-Seminoma Testicular Cancer</condition>
  <condition>Stage I Testicular Cancer</condition>
  <condition>Stage II Testicular Cancer</condition>
  <condition>Stage III Testicular Cancer</condition>
  <condition>Stage IV Testicular Cancer</condition>
  <condition>Relapse Testicular Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biomarker analysis</intervention_name>
    <description>Blood collection. Blood samples will be collected at diagnosis, during surveillance, during treatment and every 3-6 months</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood is collected in order to extract RNA.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Men with suspected and confirmed testicular germ cell cancer, aged 18-70 years. Seminomas&#xD;
        and non-seminomas, stage I-IV.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with suspected testicular cancer, referred to orchiectomy.&#xD;
&#xD;
          -  Patients diagnosed with testicular germ cell cancer.&#xD;
&#xD;
          -  Age 18-70 years of age.&#xD;
&#xD;
          -  Must be able receive information and to consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other prior or concomitant malignancy (other than testicular cancer).&#xD;
&#xD;
          -  Other diseases or conditions that hinder the ability to receive information and to&#xD;
             participate in follow-up procedures.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Testicular Germ Cell Cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mette Pernille Myklebust, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haukeland University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mette Pernille Myklebust, PhD</last_name>
    <phone>+47 41684492</phone>
    <email>mette.pernille.myklebust@helse-bergen.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olav Dahl, PhD</last_name>
    <phone>+47 55972081</phone>
    <email>olav.dahl@helse-bergen.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mette Pernille Myklebust, PhD</last_name>
      <phone>+47 41684492</phone>
      <email>mette.pernille.myklebust@helse-bergen.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haugesund Hospital</name>
      <address>
        <city>Haugesund</city>
        <zip>5528</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bogdan Stefan Bercea, MD</last_name>
      <phone>+47 52 73 20 00</phone>
      <email>bogdan.stefan.bercea@helse-fonna.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0379</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Helene Negaard, MD, PhD</last_name>
      <phone>+47 22 93 40 00</phone>
      <email>UXHEGA@ous-hf.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Norway</name>
      <address>
        <city>Tromsø</city>
        <zip>9038</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hege S. Haugnes, MD, PhD</last_name>
      <phone>+47 77 75 43 42</phone>
      <email>hege.sagstuen.haugnes@unn.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Göteborg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna G. Bergdahl, MD, PhD</last_name>
      <phone>+46 31 342 90 26</phone>
      <email>anna.grenabo@vg.region.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Thor, MD</last_name>
      <email>anna.thor@ki.se</email>
    </contact>
    <contact_backup>
      <last_name>Anders Kjellman, MD, PhD</last_name>
      <phone>+46 073 699 52 58</phone>
      <email>anders.kjellman@sll.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 31, 2021</study_first_submitted>
  <study_first_submitted_qc>June 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2021</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seminoma</mesh_term>
    <mesh_term>Testicular Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

